Welkin Health announces partnership to implement a programme to support commercialisation of the Axonics sacral neuromodulation therapy

2644

Welkin Health, a privately-held patient relationship management software company has announced that it is partnering with Axonics, a company focused on the design, development, and commercialisation of Sacral Neuromodulation (SNM) solutions. The companies will launch a programme designed to support care teams and patients implanted with the Axonics r-SNM System, the first-ever long-lived rechargeable neurostimulator for patients suffering from overactive bladder and faecal incontinence.

Welkin’s patient management software enables Axonics commercial and clinical support teams to capture and utilise relevant data to support patients and physicians.

Chase Hensel, CEO of Welkin Health said, “The programme we are building with Axonics prioritises the patient experience. This means the Axonics teams will have the pieces in place to easily manage complex data and guide workflows. We believe that having this tool in place will allow many more patients to benefit from SNM therapy and Axonics’ innovative long-lived technology.”

“We selected to work with Welkin given their software has the ability to seamlessly follow our patients during their journey from intake, through implant and post-operative programming and follow up such that patients feel supported,” commented Raymond W Cohen, CEO of Axonics. “The Welkin system promises to create efficiencies in our operations allowing us to deploy our field personnel where and when they are needed to support cases.”

(Visited 495 times, 1 visits today)

LEAVE A REPLY

Please enter your comment!
Please enter your name here